1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Acute Inflammation - Pipeline Review, H1 2014

Acute Inflammation - Pipeline Review, H1 2014

  • June 2014
  • -
  • Global Markets Direct
  • -
  • 50 pages

Acute Inflammation - Pipeline Review, H1 2014

Summary

Global Markets Direct’s, ‘Acute Inflammation - Pipeline Review, H1 2014’, provides an overview of the Acute Inflammation’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Acute Inflammation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Inflammation and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Acute Inflammation
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Acute Inflammation and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Acute Inflammation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Acute Inflammation pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Acute Inflammation
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Acute Inflammation pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Acute Inflammation - Pipeline Review, H1 2014
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Acute Inflammation Overview 6
Therapeutics Development 7
Pipeline Products for Acute Inflammation - Overview 7
Pipeline Products for Acute Inflammation - Comparative Analysis 8
Acute Inflammation - Therapeutics under Development by Companies 9
Acute Inflammation - Therapeutics under Investigation by Universities/Institutes 11
Acute Inflammation - Pipeline Products Glance 12
Clinical Stage Products 12
Early Stage Products 13
Acute Inflammation - Products under Development by Companies 14
Acute Inflammation - Products under Investigation by Universities/Institutes 15
Acute Inflammation - Companies Involved in Therapeutics Development 16
BioLineRx, Ltd. 16
Actelion Ltd 17
Forest Laboratories, Inc. 18
Italfarmaco S.p.A. 19
Alligator Bioscience AB 20
Anacor Pharmaceuticals, Inc. 21
Omeros Corporation 22
Dompe Farmaceutici S.p.A. 23
Peptinnovate Limited 24
Acute Inflammation - Therapeutics Assessment 25
Assessment by Monotherapy Products 25
Assessment by Target 26
Assessment by Mechanism of Action 29
Assessment by Route of Administration 32
Assessment by Molecule Type 34
Drug Profiles 36
ACT-389949 - Drug Profile 36
Product Description 36
Mechanism of Action 36
RandD Progress 36
ATL-1222 - Drug Profile 37
Product Description 37
Mechanism of Action 37
RandD Progress 37
CGEN-856 - Drug Profile 38
Product Description 38
Mechanism of Action 38
RandD Progress 38
ADC-1004 - Drug Profile 40
Product Description 40
Mechanism of Action 40
RandD Progress 40
DF-2156A - Drug Profile 41
Product Description 41
Mechanism of Action 41
RandD Progress 41
Selective Inhibitor of Pro Inflammatory Cytokine - Drug Profile 42
Product Description 42
Mechanism of Action 42
RandD Progress 42
AN-3485 - Drug Profile 43
Product Description 43
Mechanism of Action 43
RandD Progress 43
PIN-201104 - Drug Profile 44
Product Description 44
Mechanism of Action 44
RandD Progress 44
Small Molecule Targeting GPR32 for Acute Inflammation - Drug Profile 45
Product Description 45
Mechanism of Action 45
RandD Progress 45
Distamycin Derivatives - Drug Profile 46
Product Description 46
Mechanism of Action 46
RandD Progress 46
Acute Inflammation - Recent Pipeline Updates 47
Acute Inflammation - Dormant Projects 48
Appendix 49
Methodology 49
Coverage 49
Secondary Research 49
Primary Research 49
Expert Panel Validation 49
Contact Us 50
Disclaimer 50

List of Tables

Number of Products under Development for Acute Inflammation, H1 2014 7
Number of Products under Development for Acute Inflammation - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 10
Number of Products under Investigation by Universities/Institutes, H1 2014 11
Comparative Analysis by Clinical Stage Development, H1 2014 12
Comparative Analysis by Early Stage Development, H1 2014 13
Products under Development by Companies, H1 2014 14
Products under Investigation by Universities/Institutes, H1 2014 15
Acute Inflammation - Pipeline by BioLineRx, Ltd., H1 2014 16
Acute Inflammation - Pipeline by Actelion Ltd, H1 2014 17
Acute Inflammation - Pipeline by Forest Laboratories, Inc., H1 2014 18
Acute Inflammation - Pipeline by Italfarmaco S.p.A., H1 2014 19
Acute Inflammation - Pipeline by Alligator Bioscience AB, H1 2014 20
Acute Inflammation - Pipeline by Anacor Pharmaceuticals, Inc., H1 2014 21
Acute Inflammation - Pipeline by Omeros Corporation, H1 2014 22
Acute Inflammation - Pipeline by Dompe Farmaceutici S.p.A., H1 2014 23
Acute Inflammation - Pipeline by Peptinnovate Limited, H1 2014 24
Assessment by Monotherapy Products, H1 2014 25
Number of Products by Stage and Target, H1 2014 28
Number of Products by Stage and Mechanism of Action, H1 2014 31
Number of Products by Stage and Route of Administration, H1 2014 33
Number of Products by Stage and Molecule Type, H1 2014 35
Acute Inflammation Therapeutics - Recent Pipeline Updates, H1 2014 47
Acute Inflammation - Dormant Projects, H1 2014 48

List of Figures

Number of Products under Development for Acute Inflammation, H1 2014 7
Number of Products under Development for Acute Inflammation - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 9
Comparative Analysis by Early Stage Products, H1 2014 13
Assessment by Monotherapy Products, H1 2014 25
Number of Products by Top 10 Target, H1 2014 26
Number of Products by Stage and Top 10 Target, H1 2014 27
Number of Products by Top 10 Mechanism of Action, H1 2014 29
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 30
Number of Products by Top 10 Route of Administration, H1 2014 32
Number of Products by Stage and Top 10 Route of Administration, H1 2014 33
Number of Products by Top 10 Molecule Type, H1 2014 34
Number of Products by Stage and Top 10 Molecule Type, H1 2014 35

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation

  • $ 6995
  • Industry report
  • September 2016
  • by GBI Research

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation Summary Glioblastoma multiforme (GBM) is a grade IV tumor that arises from astrocytes. It is ...

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

  • $ 6995
  • Industry report
  • November 2016
  • by GBI Research

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation Summary Asthma is a chronic condition affecting ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.